Close Menu

Berry Genomics

Personalis said that it plans to form a wholly owned subsidiary in Shanghai, including a laboratory for local customers to use its ImmunoID NeXT platform.

PacBio will try to take the Sequel II to the clinic in China with the help of Berry Genomics and is open to partnerships globally, including with Illumina.

Illumina officials discussed several issues with investors, including the new Qiagen partnership, while at ASHG the firm introduced reagent kit upgrades.

Several groups are comparing Bionano with standard cytogenetic assays like karyotyping, FISH, or array CGH for blood cancer or genetic disease testing.

Through their joint venture, Berry and Prenetics aim to offer a range of direct-to-consumer genetic testing services to the Chinese market.

By resequencing dozens of silkworm strains, researchers gained insights into history of the silk trade and the evolutionary changes involved in domestication.

The companies will work together on a new sequencing-based NIPT technology developed by 10x Genomics for the Chinese market.

NGeneBio is moving ahead with plans to have the test cleared for diagnostic use in Korea, while envisioning a 2019 submission to the US FDA.

San Francisco Ferry Building

Executives provided updates on their companies at the 35th Annual JP Morgan Healthcare Conference in San Francisco.

The molecular diagnostic company plans to avoid the IPO process but go public in China through a reverse merger with an auto parts maker.

Pages

The Washington Post reports that Herbert Tabor, who worked at the US National Institutes of Health for 77 years, has died at 101.

The World Bank is seeking approval for a $12 billion plan to provide low-income nations with funds to procure SARS-CoV-2 vaccines, according to Reuters.

Science writes that public health officials and others are debating whether cycle threshold values should be included on SARS-CoV-2 results.

In Nucleic Acids Research this week: online database of SARS-CoV-2 protein structures, atlas of the human brain, and more.